Cessatech A/S(CESSA)
(CESSA)
Q4-rapport
Endast PDF
50 dagar sedan
0,00 DKK/aktie
Senaste utdelning
Orderdjup
Öppen
Antal
Köp
68
Sälj
Antal
1 777
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| 5 000 | AVA | DDB | ||
| 47 | AVA | DDB | ||
| 353 | AVA | DDB | ||
| 1 529 | NON | DDB | ||
| 1 777 | NON | DDB |
Volymvägt snittpris (VWAP)
6,45VWAP
6,45Omsättning (DKK)
186 142Mäklarstatistik
Mest köpt
| Mäklare | Köpt | Sålt | Netto | Internt |
|---|---|---|---|---|
| Avanza Bank AB | 12 501 | 3 307 | +9 194 | 2 030 |
| Swedbank AB | 3 580 | 0 | +3 580 | 0 |
| Nordnet Bank AB | 12 833 | 13 733 | −900 | 5 103 |
| Danske Bank A/S | 0 | 11 874 | −11 874 | 0 |
Mest sålt
| Mäklare | Köpt | Sålt | Netto | Internt |
|---|---|---|---|---|
| Danske Bank A/S | 0 | 11 874 | −11 874 | 0 |
| Nordnet Bank AB | 12 833 | 13 733 | −900 | 5 103 |
| Swedbank AB | 3 580 | 0 | +3 580 | 0 |
| Avanza Bank AB | 12 501 | 3 307 | +9 194 | 2 030 |
Företagshändelser
| Nästa händelse | |
|---|---|
| 2024 Q1-rapport | 15 maj |
| Tidigare händelser | ||
|---|---|---|
| 2023 Årsstämma | 27 mars | |
| 2023 Q4-rapport | 29 feb. | |
| 2023 Q3-rapport | 16 nov. 2023 | |
| 2023 Q2-rapport | 24 aug. 2023 | |
| 2023 Q1-rapport | 12 maj 2023 |
Data hämtas från Millistream, Quartr
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Q4-rapport
Endast PDF
50 dagar sedan
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
Företagshändelser
| Nästa händelse | |
|---|---|
| 2024 Q1-rapport | 15 maj |
| Tidigare händelser | ||
|---|---|---|
| 2023 Årsstämma | 27 mars | |
| 2023 Q4-rapport | 29 feb. | |
| 2023 Q3-rapport | 16 nov. 2023 | |
| 2023 Q2-rapport | 24 aug. 2023 | |
| 2023 Q1-rapport | 12 maj 2023 |
Data hämtas från Millistream, Quartr
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
för 1 dag sedanför 1 dag sedanPositivt nyhedsbrev fra Cessatech - Netop udsendt: INTRO A short update on our key priorities and some of the most important events for 2024 - we are off to a good start and looking forward to a year with many achievements. Thank you for reading and supporting Cessatech ! The US launch is approaching CT001 launch under the Early Access program in the US is approaching Timing Both teams have been very busy preparing for the launch under the Early Access Program in the US - and this includes both the new manufacturing setup outside New York and all the marketing activities supporting the launch. We anticipate within a few months that CT001 will reach the first hospitals. Key events Extensive planning and meetings have set the stage for a successful initial rollout, thus ensuring physicians understand the product, its profile and limitations and especially that patients have a positive experience. The first month is hence limited to selected states and hospitals before a wider distribution and promotion will take place. We will share more updates on the process after a few months on the market. Packaging and design Ventis Pharma is almost done with the final packaging, the brand name and design and we are eager to share this once the final quality assurance has been completed, as the perception testing was completed last month. This will always be important for a launch, even if it is an Early Access Program, and it becomes very real once this is final and ready to be shipped. New patent application Cessatech strengthens its patent portfolio for CT001 to treat acute pain in children, with the publication of a new U.S. patent application (US20240100035A1) to reflects our ongoing commitment to building a strong intellectual property position around our intranasal CT001 combination product. We anticipate more news regarding the application during 2025. Paediatric data to be published Paediatric data is fundamental in later potential approval and commercialisation Dental Study 0205 updates In Dec 2023 we published the positive topline data in the important Dental study 0205 supporting further advancement of CT001. The demonstrated significant reduction in on a pain scale, and although superiority was not achieved for the sufentanil control arm in adults, the co-primary endpoint of preliminary modelled exposure-response data substantiates that CT001 is superior in children. The is an important statement and the team has been working hard to publish these data in children. Modelling and simulations in Children We anticipate this important unified PK-PD model, developed based on all available both adult and paediatric study data (0201, 0204, 0205, and 0206), which are modelling and simulating exposure-response is to be published at the end of Q2 this year. This will have significant importance to the company, the regulatory process and later commercialisation of CT001.- 3 apr.3 apr.Man kunne godt tænke sig en udmelding som overgik hvad man lige forventer - for så kommer der fart på her.
2 apr.2 apr.Er der noget nyt på vej.? Har ikke lige fuldt med3 apr.3 apr.Fra oppdatering 09.01.24, mye å vente på her enda 😊 1: Focus on US launch. - The US partnership with Ventis Pharma will be one of our main priorities in 2024 initiating, the early access program. - A tech transfer of analytical methods har been completed, and sterilized vials and pumps as well as APIs are now available - production will start at the end of this month. - More details during Q1 with first sales expected in Q2. 2: Finalize study 0202 - All approvals from authorities are in place for study 0202 to be initiated at the clinical sites. Final contracts and IMP shipment will take place during Q1. - Study 0202 is the remaining safety study in children and will run in selected countries in Europe. We expect recruitment to end during 2H of 2024. 3: Build European partnership - The European market is important for our future setup. We initiated the search for a partner in 2023 and have made very good progress. We aim to have an agreement in place during 2024. Ideally, we want a partnership structure that can capture the opportunities of CT002 and potential other assets. CT002 will be initiated once this is in place.
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Q4-rapport
Endast PDF
50 dagar sedan
0,00 DKK/aktie
Senaste utdelning
Nyheter & Analyser
Nyheter och/eller generella investeringsrekommendationer alternativt utdrag därav på denna sida och relaterade länkar är framtagna och tillhandahålls av den leverantör som anges. Nordnet har inte medverkat till framtagandet, granskar inte och har inte gjort några ändringar i materialet. Läs mer om investeringsrekommendationer.
0,00 DKK/aktie
Senaste utdelning
Shareville
Delta i diskussionerna på SharevilleFå inspiration från tusentals portföljer och diskutera med andra duktiga investerare.
Logga in
- för 1 dag sedanför 1 dag sedanPositivt nyhedsbrev fra Cessatech - Netop udsendt: INTRO A short update on our key priorities and some of the most important events for 2024 - we are off to a good start and looking forward to a year with many achievements. Thank you for reading and supporting Cessatech ! The US launch is approaching CT001 launch under the Early Access program in the US is approaching Timing Both teams have been very busy preparing for the launch under the Early Access Program in the US - and this includes both the new manufacturing setup outside New York and all the marketing activities supporting the launch. We anticipate within a few months that CT001 will reach the first hospitals. Key events Extensive planning and meetings have set the stage for a successful initial rollout, thus ensuring physicians understand the product, its profile and limitations and especially that patients have a positive experience. The first month is hence limited to selected states and hospitals before a wider distribution and promotion will take place. We will share more updates on the process after a few months on the market. Packaging and design Ventis Pharma is almost done with the final packaging, the brand name and design and we are eager to share this once the final quality assurance has been completed, as the perception testing was completed last month. This will always be important for a launch, even if it is an Early Access Program, and it becomes very real once this is final and ready to be shipped. New patent application Cessatech strengthens its patent portfolio for CT001 to treat acute pain in children, with the publication of a new U.S. patent application (US20240100035A1) to reflects our ongoing commitment to building a strong intellectual property position around our intranasal CT001 combination product. We anticipate more news regarding the application during 2025. Paediatric data to be published Paediatric data is fundamental in later potential approval and commercialisation Dental Study 0205 updates In Dec 2023 we published the positive topline data in the important Dental study 0205 supporting further advancement of CT001. The demonstrated significant reduction in on a pain scale, and although superiority was not achieved for the sufentanil control arm in adults, the co-primary endpoint of preliminary modelled exposure-response data substantiates that CT001 is superior in children. The is an important statement and the team has been working hard to publish these data in children. Modelling and simulations in Children We anticipate this important unified PK-PD model, developed based on all available both adult and paediatric study data (0201, 0204, 0205, and 0206), which are modelling and simulating exposure-response is to be published at the end of Q2 this year. This will have significant importance to the company, the regulatory process and later commercialisation of CT001.
- 3 apr.3 apr.Man kunne godt tænke sig en udmelding som overgik hvad man lige forventer - for så kommer der fart på her.
- 2 apr.2 apr.Er der noget nyt på vej.? Har ikke lige fuldt med3 apr.3 apr.Fra oppdatering 09.01.24, mye å vente på her enda 😊 1: Focus on US launch. - The US partnership with Ventis Pharma will be one of our main priorities in 2024 initiating, the early access program. - A tech transfer of analytical methods har been completed, and sterilized vials and pumps as well as APIs are now available - production will start at the end of this month. - More details during Q1 with first sales expected in Q2. 2: Finalize study 0202 - All approvals from authorities are in place for study 0202 to be initiated at the clinical sites. Final contracts and IMP shipment will take place during Q1. - Study 0202 is the remaining safety study in children and will run in selected countries in Europe. We expect recruitment to end during 2H of 2024. 3: Build European partnership - The European market is important for our future setup. We initiated the search for a partner in 2023 and have made very good progress. We aim to have an agreement in place during 2024. Ideally, we want a partnership structure that can capture the opportunities of CT002 and potential other assets. CT002 will be initiated once this is in place.
Kommentarerna ovan kommer från användare på Nordnets sociala nätverk Shareville och har varken redigerats eller på förhand granskats av Nordnet. Det innebär inte att Nordnet tillhandahåller investeringsrådgivning eller investeringsrekommendationer. Nordnet påtar sig inget ansvar för kommentarerna eller eventuella felaktigheter i automatiska översättningar.
Orderdjup
Öppen
Antal
Köp
68
Sälj
Antal
1 777
Senaste avslut
| Tid | Pris | Antal | Köpare | Säljare |
|---|---|---|---|---|
| 5 000 | AVA | DDB | ||
| 47 | AVA | DDB | ||
| 353 | AVA | DDB | ||
| 1 529 | NON | DDB | ||
| 1 777 | NON | DDB |
Volymvägt snittpris (VWAP)
6,45VWAP
6,45Omsättning (DKK)
186 142Mäklarstatistik
Mest köpt
| Mäklare | Köpt | Sålt | Netto | Internt |
|---|---|---|---|---|
| Avanza Bank AB | 12 501 | 3 307 | +9 194 | 2 030 |
| Swedbank AB | 3 580 | 0 | +3 580 | 0 |
| Nordnet Bank AB | 12 833 | 13 733 | −900 | 5 103 |
| Danske Bank A/S | 0 | 11 874 | −11 874 | 0 |
Mest sålt
| Mäklare | Köpt | Sålt | Netto | Internt |
|---|---|---|---|---|
| Danske Bank A/S | 0 | 11 874 | −11 874 | 0 |
| Nordnet Bank AB | 12 833 | 13 733 | −900 | 5 103 |
| Swedbank AB | 3 580 | 0 | +3 580 | 0 |
| Avanza Bank AB | 12 501 | 3 307 | +9 194 | 2 030 |
Företagshändelser
| Nästa händelse | |
|---|---|
| 2024 Q1-rapport | 15 maj |
| Tidigare händelser | ||
|---|---|---|
| 2023 Årsstämma | 27 mars | |
| 2023 Q4-rapport | 29 feb. | |
| 2023 Q3-rapport | 16 nov. 2023 | |
| 2023 Q2-rapport | 24 aug. 2023 | |
| 2023 Q1-rapport | 12 maj 2023 |
Data hämtas från Millistream, Quartr